

III INTERNATIONAL CONFERENCE ON
**CANCER RESEARCH AND
TARGETED THERAPY**

August 6-8, 2018

Venue

Renaissance London Heathrow Hotel

Bath Road, Hounslow

England TW6 2AQ

United Kingdom

8:00 -12:00 Keynote Lectures-I

TBA

Andrew V. Schally, University of Miami, USA

The proton preparation NSC-631570 (UKRAIN) and its selective effect

Techn. Wassil Nowicky, Ukrainian Anti-Cancer Institute, Austria

Resistance to tyrosine kinase-targeted therapy in lung cancer: autophagy and metabolic changes

Olivier E Pardo, Imperial College, London

Break

Role of mTOR in the tumor endothelium

Olivier Dormond, CHUV, Switzerland

Pancreatic cancer dictates an inflammatory mediated tumorigenesis in the host microenvironment

Myron R Szewczuk, Queen's University, Kingston, Ontario, Canada

Biology of cell-free nucleic acids and their role in initiation, progression and metastasis of cancer

Indraneel Mitra, Tata Memorial Centre, India

12:00-13:00 Lunch

13:00-15:00 Keynote Lectures-II

TBA

Chellappan Srikumar, Moffitt Cancer Center & Research Institute, Florida, USA

IL-1-activated signaling pathways induce resistance to cisplatin through Δ NP63 in breast cancer cells

Isaura Meza, CINVESTAV-IPN, Mexico

Heme and vascular disrupting agent in non-small cell lung cancer

Li Zhang, The University of Texas at Dallas, Texas, USA

Break

Effects of far-infrared & terahertz onnetsu therapy on rheumatoid arthritis and various cancers

Kazuko Tatsumura, Gaia Holistic Health, New York, USA

15:00-17:00 Session I Cancer Biology

Polyol pathway as a novel therapeutic target for aggressive tumors

Paolo Ceppi, Uniklinikum Erlangen, IZKF Junior Group 1, Nikolaus-Fiebiger-Zentrum, Germany

Building better and safer NSAIDs: Development and therapeutic potential of hybrids that release nitric oxide and hydrogen sulfide

Khosrow Kashfi, City University of New York School of Medicine, New York, USA

Therapeutic resistance in cancer: role of quercetin

Mukerrem Betül Yerer Aycan, University of Erciyes, Turkey

Second generation proteasome inhibitors: Side effects and potency in cancer therapy

Betul Karademir, School of Medicine, University of Marmara, Turkey

T cell co-stimulation vulnerable to breach by cancer cells in the tumor microenvironment

Per thor Straten, University Hospital Herlev, University of Copenhagen, Denmark

Day-2 | August 7, 2018

8:30-12:30

Symposium

Immunotherapy Of Cancer: Triumphs And Challenges And The Impact Of Immunosenescence

Chairman

Dr.Graham Pawelec

Targeting caspase-8-dependent apoptosis in cancer cells to enhance immunotherapy

Thomas Sayers, NIH/NCI Frederick, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Maryland, USA

TBA

Indraneel Mitra, Tata Memorial Centre, India

Cancer immune-monitoring; challenges of big data management

Shahram Kordasti, King's College London, UK

Immunotherapy of cancer: triumphs and challenges and the impact of immunosenescence

Graham Pawelec, University of Tuebingen Center for Medical Research (ZMF), Germany

Break

Inactivation of type I interferon pathway as a critical determinant of immune suppressive tumor microenvironment

Serge Y Fuchs, University of Pennsylvania, Philadelphia, USA

Co-inhibitory immune signaling generates the splicing of an immunophilin which marks a highly suppressive Tregs subset

Maria Fiammetta Romano, University of Naples Federico, Italy

Cancer immunotherapy with low-level whole-body exposures to ionizing radiation

Marek K. Janiak, Military Institute of Hygiene and Epidemiology, Poland

12:30-13:30 Lunch

Selective Anti-cancer Drug NSC631570 Re-educates Alternatively Activated Phagocytes

Larysa M Skivka, Taras Shevchenko National University of Kyiv, Ukraine

Tumour infiltrating lymphocyte therapy; melanoma and beyond

Gray Kueberuwa, The University of Manchester, UK

16:00-17:00 Posters

9:00-13:00 **Types Of Cancer & Biomarkers**

Therapeutic Targeting of Osteopontin and Integrin in Triple Negative Breast Cancer

Dr. Gopal C. Kundu, National Centre for Cell Science, India

CDK 4/6 inhibitors beyond estrogen receptor positive breast cancer: synergistic effect of PI3K and CDK4/6 in triple negative breast cancer

Yuan Yuan, City Of Hope, California, USA

Association of ring box-1 protein overexpression With clinicopathologic prognostic parameters in prostate carcinoma

Zeliha Esin Celik, Selcuk University TURKEY

High RAC3 expression levels are required for induction and maintaining of cancer cell stemness

Mónica A. Costas, Universidad de Buenos Aires, Argentina

Break

Targeting Neuraminidase-1 with multi-modal therapy to sensitize pancreatic cancer to chemotherapy and moderate the inflammatory microenvironment

Bessi Qorri, Queen's University, Kingston, Ontario, Canada

Aspirin, oseltamivir phosphate, and metformin sensitize 3D triple-negative breast cancer spheroids to tamoxifen treatment

Nicka Kalaydina, Queen's University, Kingston, Ontario, Canada

Postmastectomy chest wall reirradiation with proton therapy for breast cancer

Lisa McGee, Mayo Clinic Arizona, Arizona, USA

Biomarker identification and neuromodulation as treatment for chronic chemotherapy-induced peripheral neuropathy

Sarah Prinsloo, The University of Texas MD Anderson Cancer Center, Teaxs, USA

The Tumour Suppressor OPCML Prevents AXL-mediated EMT and Motility in Ovarian Cancer Cells

Sarah Prinsloo, The University of Texas MD Anderson Cancer Center, Teaxs, USA

TBA

Dae Ro Lim, Soonchunhyang University Bucheon Hospital, Korea

Cancer Vaccines and the impact of g-irradiation on the induction of bystander killing by genetically engineered ovarian tumor cells: implications for clinical use

Jehad Zweiri, University of Liverpool Medical School UK

TBA

Tijen Atacag, Dr. Suat Gonsel Kyrenia University

Posters

- P-01 Synthesis and Bio-Applications of Luminescent Transition-Metal Complexes**
Haitao Wang, Hong Kong Baptist University, China
- P-02 Prognostic variables and their potential roles in the development of autoimmune thyroid disorders in breast cancer**
Arif Malik, University of Lahore, Pakistan
- P-03 TBA**
Muhammad Abdul Basit Ashraf, University of Lahore, Pakistan
- P-04 TBA**
Sulayman Waquar, University of Lahore, Pakistan
- P-05 Gestational Trophoblastic Diseases: A Seven-year observational study in the city of Duhok – Iraq**
Eleana Ayou, Azadi Teaching Hospital, Iraq
- P-06 Study on the mechanism of deacetylase sirt3 regulating mutant p53 induced apoptosis in lung cancer cells**
Yanan Liu, Jilin University, China
- P-07 p62/SQSTM1 regulates LC3-Caspase8 complex mediating cisplatin induced apoptosis**
Jing SU, Jilin University, China
- P-08 PGC1 α promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondria biogenesis**
Liankun SUN, JILIN University, China
- P-09 Breast self-examination knowledge and practice among Kuwaiti women**
Maha Al-Sejari, Kuwait University, Kuwait
- P-10 Protective role of magic fruit and honey bee against human hepatocarcinogenesis**
Mofeed Selim, National Cancer Institute, Egypt

If you wish to submit abstract please contact

Kinnera Kalagara

Email: kkalagara@uniscigroup.net

cancer.therapy@uniscigroup.org



<https://www.linkedin.com/in/3rd-cancer-research-targeted-therapy-conference-612600118/>



UNITED | Scientific
Group

8105, Rasor Blvd - Suite #112, PLANO, TX 75024, USA

Ph: +1-408-426-4832, +1-408-426-4833

Toll Free: +1-844-395-4102; Fax: +1-408-426-4869

Email: cancer.therapy@uniscigroup.org

Web: www.unitedscientificgroup.com/conferences/cancer-research-therapy